The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
Activist Investor Thinks Merck Undervalues Acceleron Buy
Hours after Merck & Co Inc's (NYSE: MRK) announcement to acquire Acceleron Pharma Inc (NASDAQ: XLRN), one of Acceleron's activist investors isn't happy with the price tag.
Expert Ratings For Acceleron Pharma
Analysts have provided the following ratings for Acceleron Pharma (NASDAQ:XLRN) within the last quarter:
Morgan Stanley Downgrades Acceleron Pharma to Equal-Weight, Announces $180 Price Target
Morgan Stanley analyst Jeffrey Hung downgrades Acceleron Pharma (NASDAQ:XLRN) from Overweight to Equal-Weight and announces $180 price target.
10 Biggest Price Target Changes For Friday
JP Morgan lowered the price target on Spirit Airlines, Inc. (NYSE: SAVE) from $43 to $34. Spirit Airlines shares fell 1.4% to $25.57 in pre-market trading.
Barclays Downgrades Acceleron Pharma to Equal-Weight, Raises Price Target to $180
Barclays analyst Carter Gould downgrades Acceleron Pharma (NASDAQ:XLRN) from Overweight to Equal-Weight and raises the price target from $150 to $180.
Cowen & Co. Downgrades Acceleron Pharma to Market Perform, Raises Price Target to $180
Cowen & Co. analyst Yaron Werber downgrades Acceleron Pharma (NASDAQ:XLRN) from Outperform to Market Perform and raises the price target from $173 to $180.
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020
Believes Acceleron Has Significant Momentum Given Recent Positive Data
HC Wainwright & Co. Downgrades Acceleron Pharma to Neutral, Raises Price Target to $180
HC Wainwright & Co. analyst Edward White downgrades Acceleron Pharma (NASDAQ:XLRN) from Buy to Neutral and raises the price target from $168 to $180.